-transparent.png){kind=logo}
The pharmacokinetics and metabolic chiral inversion of the S(+)- and R(-)-enantiomers of tiaprofenic acid (S-TIA, R-TIA) were assessed in vivo in rats, and in addition the biochemistry of inversion was investigated in vitro in rat liver homogenates. Drug enantiomer concentrations in plasma were investigated following administration of S-TIA and R-TIA (i.p. 3 and 9 mg/kg) over 24 hr. Plasma concentrations of TIA enantiomers were determined by stereospecific HPLC analysis. After administration of R-TIA it was found that 1) there was a time delay of peak S-TIA plasma concentrations, 2) S-TIA concentrations exceeded R-TIA concentrations from approximately 2 hr after dosing, 3) Cmax and AUC(0-infinity) for S-TIA were greater than for R-TIA following administration of S-TIA, and 4) inversion was bidirectional but favored inversion of R-TIA to S-TIA. Bidirectional inversion was also observed when TIA enantiomers were incubated with liver homogenates up to 24 hr. However, the rate of inversion favored transformation of the R-enantiomer to the S-enantiomer. In conclusion, stereoselective pharmacokinetics of R- and S-TIA were observed in rats and bidirectional inversion in rat liver homogenates has been demonstrated for the first time. Chiral inversion of TIA may involve metabolic routes different from those associated with inversion of other 2-arylpropionic acids such as ibuprofen.
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
April 1989,
Xenobiotica; the fate of foreign compounds in biological systems,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
January 1992,
Chirality,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
May 1985,
British journal of clinical pharmacology,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
October 1994,
British journal of clinical pharmacology,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
August 1991,
Journal of clinical pharmacology,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
December 2004,
British journal of clinical pharmacology,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
September 1978,
Xenobiotica; the fate of foreign compounds in biological systems,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
May 1988,
Clinical pharmacology and therapeutics,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
May 1989,
Circulation,
K Erb, and
R Brugger, and
K Williams, and
G Geisslinger
September 1991,
Pharmaceutical research,
